DK2516469T3 - ANTI-HER3-antistoffer og anvendelser deraf - Google Patents
ANTI-HER3-antistoffer og anvendelser deraf Download PDFInfo
- Publication number
- DK2516469T3 DK2516469T3 DK10798541.8T DK10798541T DK2516469T3 DK 2516469 T3 DK2516469 T3 DK 2516469T3 DK 10798541 T DK10798541 T DK 10798541T DK 2516469 T3 DK2516469 T3 DK 2516469T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- leu
- val
- antibody
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (14)
1. Antistof der binder til humant HER3, kendetegnet ved at det tungkæde-variable domæne VH er SEQ ID NO:8; og det letkæde-variable domæne VL er SEQ ID NO:9, eller det letkæde-variable domæne VL er SEQ ID NO: 10, eller det letkæde-variable domæne VL er SEQ ID NO: 11.
2. Antistoffet ifølge krav 1, kendetegnet ved at det tungkæde-variable domæne VH er SEQ ID NO:8; og det letkæde-variable domæne VL er SEQ ID NO:9, eller det letkæde-variable domæne VL er SEQ ID NO: 11.
3. Antistoffet ifølge krav 1, kendetegnet ved at det tungkæde-variable domæne VH er SEQ ID NO:8; og det letkæde-variable domæne VL er SEQ ID NO: 10.
4. Antistoffet ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved at antistoffet er monoklonalt.
5. Antistoffet ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved at antistoffet er af IgGl-underklasse.
6. Antistoffet ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved at antistoffet er glycosyleret med en sukkerkæde ved Asn297 hvorved mængden af fucose i denne sukkerkæde er 65% eller derunder.
7. Antistoffet ifølge krav 6, hvorved mængden af fucose i denne sukkerkæde er mellem 5 og 65%.
8. Farmaceutisk sammensætning kendetegnet ved at omfatte et antistof ifølge et hvilket som helst af kravene 1 til 7.
9. Antistof ifølge et hvilket som helst af kravene 1 til 7 til anvendelse i behandlingen af cancer.
10. Anvendelse af et antistof ifølge et hvilket som helst af kravene 1 til 7 til fremstillingen af et medikament til behandlingen af cancer.
11. Nukleinsyre der koder for en tung- og letkæde af et antistof der binder til humant HER3, kendetegnet ved at antistoffet omfatter et variabelt domæne VH af SEQ ID NO:8; og et let kæde-variabelt domæne VL af SEQ ID NO:9, SEQ ID NO: 10, eller SEQ ID NO:ll.
12. Ekspressionsvektor kendetegnet ved at omfatte en nukleinsyre ifølge krav 11 til ekspression af antistoffet ifølge et hvilket som helst af kravene 1 til 7 i en prokaryot eller eukaryot værtscelle.
13. Prokaryot eller eukaryot værtscelle omfattende en vektor ifølge krav 12.
14. Fremgangsmåde til fremstillingen af et rekombinant antistof ifølge kravene 1 til 7, kendetegnet ved ekspression afen nukleinsyre ifølge krav 11 i en prokaryot eller eukaryot værtscelle og genvinde antistoffet fra cellen eller cellekultursupernatanten.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09015831 | 2009-12-22 | ||
PCT/EP2010/070062 WO2011076683A1 (en) | 2009-12-22 | 2010-12-17 | Anti-her3 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2516469T3 true DK2516469T3 (da) | 2016-05-02 |
Family
ID=42126432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10798541.8T DK2516469T3 (da) | 2009-12-22 | 2010-12-17 | ANTI-HER3-antistoffer og anvendelser deraf |
Country Status (33)
Country | Link |
---|---|
US (4) | US8859737B2 (da) |
EP (1) | EP2516469B1 (da) |
JP (2) | JP5680671B2 (da) |
KR (2) | KR20140130751A (da) |
CN (1) | CN102822201B (da) |
AR (1) | AR079551A1 (da) |
AU (1) | AU2010335282B2 (da) |
BR (1) | BR112012015255A2 (da) |
CA (1) | CA2782571C (da) |
CL (1) | CL2012001649A1 (da) |
CO (1) | CO6551674A2 (da) |
CR (1) | CR20120284A (da) |
CY (1) | CY1117563T1 (da) |
DK (1) | DK2516469T3 (da) |
EC (1) | ECSP12011995A (da) |
ES (1) | ES2571226T3 (da) |
HK (1) | HK1175183A1 (da) |
HR (1) | HRP20160737T1 (da) |
HU (1) | HUE029026T2 (da) |
IL (1) | IL220162A (da) |
MA (1) | MA33892B1 (da) |
MX (1) | MX2012007340A (da) |
MY (1) | MY161909A (da) |
NZ (1) | NZ600262A (da) |
PE (1) | PE20121616A1 (da) |
PL (1) | PL2516469T3 (da) |
RS (1) | RS54795B1 (da) |
RU (1) | RU2560583C2 (da) |
SG (1) | SG181894A1 (da) |
SI (1) | SI2516469T1 (da) |
TW (1) | TWI421092B (da) |
UA (1) | UA107821C2 (da) |
WO (1) | WO2011076683A1 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
MX2011010166A (es) * | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
SI2516469T1 (sl) * | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
MX348739B (es) | 2010-03-10 | 2017-06-27 | F Hoffmann-La Roche Ag * | Metodo para purificar soluciones de inmunoglobulina. |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
JP6057896B2 (ja) | 2010-08-20 | 2017-01-11 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
ITRM20100577A1 (it) * | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
US20120258073A1 (en) | 2011-02-10 | 2012-10-11 | Christian Gerdes | Immunotherapy |
JP2014509593A (ja) | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ErbB経路阻害剤に対する耐性の克服 |
BR112013027021A2 (pt) | 2011-04-19 | 2016-11-29 | Merrimack Pharmaceuticals Inc | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
PL2748202T3 (pl) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Dwuswoiste cząsteczki wiążące antygen |
BR112014007382A2 (pt) | 2011-09-30 | 2017-04-04 | Regeneron Pharma | anticorpos anti-erbb3 e seus usos |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
AU2012318541B2 (en) | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
BR112014012539B1 (pt) * | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
CN108341873B (zh) | 2011-12-05 | 2022-03-25 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
EP2882777B1 (en) | 2012-08-07 | 2018-10-10 | Roche Glycart AG | Composition comprising two antibodies engineered to have reduced and increased effector function |
AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
US9725520B2 (en) * | 2013-03-14 | 2017-08-08 | The Board Of Regents Of The University Of Texas System | HER3 specific monoclonal antibodies for diagnostic and therapeutic use |
AU2014239903A1 (en) | 2013-03-14 | 2015-09-17 | Genentech, Inc. | Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use |
CA3071678A1 (en) * | 2013-04-16 | 2014-10-23 | Genentech,Inc. | Pertuzumab variants and evaluation thereof |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
US10519247B2 (en) * | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
CA2944892A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 |
KR20160144465A (ko) | 2014-05-14 | 2016-12-16 | 에프. 호프만-라 로슈 아게 | Her3의 베타-헤어핀에 결합하는 항-her3 항체 |
CN110642952B (zh) * | 2014-08-14 | 2021-05-25 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2016366521A1 (en) | 2015-12-11 | 2018-06-21 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or preventing growth of tumors resistant to EGFR and/or ErbB3 blockade |
WO2017160990A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
PE20211696A1 (es) | 2018-12-21 | 2021-09-01 | Hoffmann La Roche | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
JP3925943B2 (ja) | 1996-03-27 | 2007-06-06 | ジェネンテック インコーポレーテッド | ErbB3抗体 |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
EP1495123B1 (en) | 2002-03-26 | 2013-10-30 | Zensun (Shanghai) Science and Technology Limited | Erbb3 based methods and compositions for treating neoplasms |
ATE475708T1 (de) | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
CA2544865C (en) | 2003-11-05 | 2019-07-09 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
JP2008512479A (ja) | 2004-09-08 | 2008-04-24 | ジェネンテック・インコーポレーテッド | デスレセプターリガンド及びcd20抗体の使用方法 |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
US20090215639A1 (en) | 2005-04-26 | 2009-08-27 | Bioren, Inc. | Method of Producing Human IgG Antibodies with Enhanced Effector Functions |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
RU2482132C2 (ru) | 2005-08-26 | 2013-05-20 | Роше Гликарт Аг | Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
AU2007324868B2 (en) | 2006-11-28 | 2014-03-20 | Daiichi Sankyo Europe Gmbh | Activated HER3 as a marker for predicting therapeutic efficacy |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
PT2716301T (pt) * | 2007-02-16 | 2017-07-04 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
EP2138511A1 (en) | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
MX2011010166A (es) * | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
BR112012003809A2 (pt) | 2009-08-21 | 2019-09-24 | Merrimack Pharmaceuticals Inc | anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. |
WO2011044311A2 (en) | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
EP2496598B1 (en) | 2009-11-04 | 2017-08-02 | Affibody AB | Her3 binding polypeptides |
PT3351558T (pt) | 2009-11-13 | 2020-04-09 | Daiichi Sankyo Europe Gmbh | Material e métodos para tratamento ou prevenção de doenças associadas a her-3 |
SI2516469T1 (sl) * | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
JP2013540694A (ja) | 2010-08-06 | 2013-11-07 | ウー3・フアルマ・ゲー・エム・ベー・ハー | Her3結合剤の前立腺治療における使用 |
JP6057896B2 (ja) | 2010-08-20 | 2017-01-11 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2811747A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her3 antibodies |
CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
EP2635604B1 (en) | 2010-11-01 | 2016-11-30 | Symphogen A/S | Pan-her antibody composition |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
ITRM20100577A1 (it) | 2010-11-02 | 2012-05-03 | Takis Srl | Immunoterapia contro il recettore erbb-3 |
BR112014007382A2 (pt) | 2011-09-30 | 2017-04-04 | Regeneron Pharma | anticorpos anti-erbb3 e seus usos |
-
2010
- 2010-12-17 SI SI201031158A patent/SI2516469T1/sl unknown
- 2010-12-17 RS RS20160292A patent/RS54795B1/sr unknown
- 2010-12-17 NZ NZ600262A patent/NZ600262A/xx not_active IP Right Cessation
- 2010-12-17 ES ES10798541T patent/ES2571226T3/es active Active
- 2010-12-17 PL PL10798541T patent/PL2516469T3/pl unknown
- 2010-12-17 KR KR20147029079A patent/KR20140130751A/ko not_active Application Discontinuation
- 2010-12-17 RU RU2012129735/10A patent/RU2560583C2/ru not_active IP Right Cessation
- 2010-12-17 PE PE2012000881A patent/PE20121616A1/es not_active Application Discontinuation
- 2010-12-17 JP JP2012545255A patent/JP5680671B2/ja active Active
- 2010-12-17 MX MX2012007340A patent/MX2012007340A/es active IP Right Grant
- 2010-12-17 CA CA2782571A patent/CA2782571C/en not_active Expired - Fee Related
- 2010-12-17 WO PCT/EP2010/070062 patent/WO2011076683A1/en active Application Filing
- 2010-12-17 MY MYPI2012002818A patent/MY161909A/en unknown
- 2010-12-17 KR KR1020127019170A patent/KR20120098911A/ko not_active IP Right Cessation
- 2010-12-17 EP EP10798541.8A patent/EP2516469B1/en active Active
- 2010-12-17 MA MA35018A patent/MA33892B1/fr unknown
- 2010-12-17 AU AU2010335282A patent/AU2010335282B2/en not_active Ceased
- 2010-12-17 DK DK10798541.8T patent/DK2516469T3/da active
- 2010-12-17 CN CN201080064271.3A patent/CN102822201B/zh active Active
- 2010-12-17 US US12/971,300 patent/US8859737B2/en active Active
- 2010-12-17 UA UAA201208617A patent/UA107821C2/uk unknown
- 2010-12-17 BR BR112012015255A patent/BR112012015255A2/pt not_active IP Right Cessation
- 2010-12-17 HU HUE10798541A patent/HUE029026T2/en unknown
- 2010-12-17 SG SG2012046587A patent/SG181894A1/en unknown
- 2010-12-20 AR ARP100104773A patent/AR079551A1/es unknown
- 2010-12-21 TW TW099145048A patent/TWI421092B/zh not_active IP Right Cessation
-
2012
- 2012-05-28 CR CR20120284A patent/CR20120284A/es unknown
- 2012-06-04 IL IL220162A patent/IL220162A/en not_active IP Right Cessation
- 2012-06-18 CL CL2012001649A patent/CL2012001649A1/es unknown
- 2012-06-21 EC ECSP12011995 patent/ECSP12011995A/es unknown
- 2012-06-27 CO CO12108245A patent/CO6551674A2/es active IP Right Grant
-
2013
- 2013-02-26 HK HK13102373.8A patent/HK1175183A1/xx unknown
-
2014
- 2014-09-08 US US14/480,198 patent/US9611331B2/en active Active
- 2014-09-08 US US14/480,192 patent/US20140377272A1/en not_active Abandoned
-
2015
- 2015-01-06 JP JP2015001019A patent/JP2015109848A/ja active Pending
-
2016
- 2016-05-13 CY CY20161100414T patent/CY1117563T1/el unknown
- 2016-06-24 HR HRP20160737TT patent/HRP20160737T1/hr unknown
-
2017
- 2017-02-17 US US15/436,267 patent/US10196456B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10196456B2 (en) | Anti-HER3 antibodies and uses thereof | |
US9346886B2 (en) | Humanized anti-CDCP1 antibodies | |
EP2943508B1 (en) | Combination therapy of anti-her3 and anti-her2 antibodies | |
US8883159B2 (en) | Antibodies against CDCP1 for the treatment of cancer |